Roth Capital On Allena Also Notes 'Will docs prescribe reloxaliase? According to our proprietary survey, its therapeutic profile (20% UOx reduction and clean safety) is exactly what they are looking for to treat EH patients'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/07/2019 18:12